AuditLine › HHS OIG › Centers for Medicare and Medicaid Services
HHS OIG recommendation 14-E-03-048.02
CMS should explore the possibility of requiring providers to identify on the Part B claim the pharmacy that produced the compounded drug.
The recommendation, in the publisher's words
CMS should explore the possibility of requiring providers to identify on the Part B claim the pharmacy that produced the compounded drug.
- Responsible agency
- Centers for Medicare and Medicaid Services
- Issued
- April 29, 2014
- Report
- Compounded Drugs Under Medicare Part B: Payment and Oversight (OEI-03-13-00270) · find it at HHS OIG
- Kind of report
- Evaluation
- Agency response
- Non-Concur (as recorded by the publisher)
- Closed
- March 22, 2024 (publisher's date)
- Publisher topics
- Food; Drug and Device Safety, Prescription Drug
“Open” and “closed” are the publisher's words. AuditLine repeats them with the date it read them. It does not check whether a recommendation was carried out, and a closed recommendation is not proof that a problem was fixed.
Dated history
- Issued by HHS OIG. (publisher's date)
- Closed, with status “Closed Unimplemented”. (publisher's date)
- First recorded by AuditLine. (start of AuditLine's own history for this record)
Dates marked "publisher's date" come from the publisher's file. AuditLine's own observations begin November 10, 2026 and are added each time the publisher's file changes.
Other recommendations from this report
1 more, of which 1 is open in the publisher's file.
- CMS should explore the possibility of conducting descriptive analyses of Part B claims for compounded drugs.HHS OIG 14-E-03-048.03 · issued Apr 29, 2014Open Unimplemented
Source
Open this report in HHS OIG's tracker This publisher's records (CSV)
Official export: https://oig.hhs.gov/recommendations/export-recs/. File read , 4,677 rows,
SHA-256 664fdfb3658ecb72…. HHS OIG's status, response, dates and potential-savings labels are the publisher's own claims.